The global neuroblastoma market is expected to grow steadily over the forecast period. It is projected that the market held a market value of USD 2.60 billion in 2016 and is projected to grow at a CAGR of 3.7% over the forecast period. Neuroblastoma is a common cancer detected in infants. Neuroblastoma develops from immature nerve cells found in various parts of the body. It most commonly occurs in children or young ones below 5 years old. The patient having neuroblastoma may cause symptoms such as backbone pain, weight loss, abdominal pain, enlarged stomach, bulging eyes, weight, crankiness, anemia, fever, bone pain, dark circles around the eyes, weakness, high blood pressure, and constipation or diarrhea.
Segmentation
The global neuroblastoma market has been segmented into diagnostics, treatment, and end user.
The market, on the basis of diagnostics, has been segmented into various tests, MIBG scan, imaging, and biopsy. The tests are further sub-segmented into bone marrow, tissue, urine, and blood.
The market, by treatment, has been segmented into surgery, chemotherapy, radiation therapy, stem cell transplant, immunotherapy, and monoclonal antibody treatment. The market, by end user, has been segmented into hospitals ambulatory surgical centers, diagnostic centers, research centers, and others.
Key players
United Therapeutics Corp., APEIRON Biologics AG, LUMITOS AG, NANTGE Healthcare, Pfizer Inc., GL Pharm Tech Corporation, Aetna Inc, RxStrategies, Inc., and others are some of the key players in the global neuroblastoma market.
Global Neuroblastoma Market, by Diagnostics
- Bone Marrow Testing
- Tissue Testing
- Urine and Blood Testing
Global Neuroblastoma Market, by Treatment
- Medications
- Surgery
- Chemotherapy
- Radiation therapy
- Stem Cell Transplant
- Immunotherapy
- Monoclonal antibody treatment
Global Neuroblastoma Market, by End User
- Hospitals and clinics
- Ambulatory Surgical Centers
- Diagnostic Centers
- Research centers
- Others
Request Customization
Get a Sample
Get a Sample
Request Customization